Gilad Gordon

Gilad Gordon, MD, MBA

President, ORRA Group, LLC and Associate Clinical Professor of Medicine, University of Colorado School of Medicine

Dr. Gilad Gordon is an expert in clinical development of vaccines and other therapeutics with over 30 years of experience in the field working with both large and small organizations.  Dr. Gordon has served in various senior positions at a number of large and small bio-pharmaceutical firms.  As Chief Medical Officer at Inviragen, Dr. Gordon led the clinical team which designed and implemented the multi-nation Phase 1 and Phase 2 trials for a novel vaccine for dengue fever and a vaccine for hand, foot and mouth disease.  The company was ultimately sold to Takeda which recently succeeded in a worldwide Phase 3 trial of the dengue vaccine and is currently applying for regulatory approval.  Dr. Gordon attended Harvard College and received his MD from the Harvard-MIT Program in Health Sciences and Technology at Harvard Medical School.  He is Board certified in Internal Medicine and received his MBA from the University of Washington.   Dr. Gordon is a Clinical Associate Professor of Medicine at the  University of Colorado School of Medicine and lives in Boulder, CO.